Study guide

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks

Key Takeaways Explain This Topic AI

Life-threatening asthma features include peak flow below 33% predicted, oxygen saturation below 92%, silent chest, cyanosis, exhaustion, arrhythmia and altered consciousness.

A normal or rising PaCO2 in acute asthma signals exhaustion and near-fatal disease, and mandates immediate critical care referral.

All patients admitted with acute asthma need oral prednisolone 40-50 mg daily for at least five days, continued alongside their inhaled corticosteroid.

Last updated: September 2026

Obstructive airway diseases constitute one of the most heavily tested domains in MRCP(UK) Part 1. Candidates must demonstrate command of objective diagnostic cut-offs, evidence-based chronic escalation pathways (including Maintenance and Reliever Therapy [MART] and biologicals), the clinical distinction between acute severe and life-threatening asthma, and the physiological principles underpinning controlled oxygen and non-invasive ventilation in chronic obstructive pulmonary disease (COPD).

1. Asthma: Diagnostic Principles & Objective Testing (BTS/NICE/SIGN 2024)

Asthma is a heterogeneous disorder characterized by chronic airway inflammation, variable expiratory airflow limitation, and airway hyperresponsiveness. Clinical symptoms (wheeze, breathlessness, chest tightness, nocturnal cough) possess poor diagnostic specificity alone. UK practice is now governed by the joint BTS/NICE/SIGN asthma guideline published on 27 November 2024 (NICE NG245) , which replaced NICE NG80 and the chronic-management sections of the 2019 BTS/SIGN guideline (SIGN 158). It strictly mandates objective physiological and biological confirmation before a diagnosis is made, and it sets FeNO and blood eosinophil count as the preferred first-line diagnostic tests in adults. Note that NG245 covers diagnosis, monitoring and chronic management only - acute attacks and severe asthma remain outside its scope and are covered by the separate BTS/SIGN acute asthma guidance used below.

Objective Diagnostic Criteria

Fractional Exhaled Nitric Oxide (FeNO): Nitric oxide is produced by inducible nitric oxide synthase (iNOS) upregulated by interleukin-4 (IL-4) and interleukin-13 (IL-13) in eosinophilic, Type 2 helper T cell (Th2)-mediated airway inflammation.

FeNO ≥ 40 ppb \text{FeNO} \ge 40\text{ ppb} FeNO ≥ 40 ppb in adults ( ≥ 35 ppb \ge 35\text{ ppb} ≥ 35 ppb in children) is positive, highly suggestive of eosinophilic inflammation and responsiveness to inhaled corticosteroids (ICS).

Values between 25 – 39 ppb 25\text{–}39\text{ ppb} 25 – 39 ppb represent an intermediate gray zone; < 25 ppb < 25\text{ ppb} < 25 ppb makes active eosinophilic asthma unlikely.

Spirometry & Bronchodilator Reversibility (BDR):

Obstructive defect: Post-bronchodilator FEV 1 / FVC < 0.70 \text{FEV}_1/\text{FVC} < 0.70 FEV 1 ​ / FVC < 0.70 (or below the lower limit of normal [LLN]).

Positive BDR: An improvement in FEV 1 \text{FEV}_1 FEV 1 ​ of ≥ 12 % \ge 12\% ≥ 12% AND ≥ 200 mL \ge 200\text{ mL} ≥ 200 mL measured 15–20 minutes following 400 μ g 400\ \mu\text{g} 400 μ g inhaled salbutamol via a spacer.

Peak Expiratory Flow (PEF) Variability:

Monitored twice daily (morning and evening) over a minimum of 2 to 4 weeks.

Diurnal variability > 20 % > 20\% > 20% calculated as: [ ( Highest PEF − Lowest PEF ) / Mean PEF ] × 100 [(\text{Highest PEF} - \text{Lowest PEF}) / \text{Mean PEF}] \times 100 [( Highest PEF − Lowest PEF ) / Mean PEF ] × 100 .

Direct Bronchial Provocation Challenge:

Performed in specialized lung function laboratories when spirometry and FeNO are equivocal.

Inhaled methacholine or histamine: A provocative concentration causing a 20 % 20\% 20% fall in FEV 1 \text{FEV}_1 FEV 1 ​ ( PC 20 \text{PC}_{20} PC 20 ​ ) of ≤ 8 mg/mL \le 8\text{ mg/mL} ≤ 8 mg/mL confirms bronchial hyperresponsiveness.

2. Chronic Asthma: Stepwise Pharmacological Management Ladder

Contemporary management prioritizes anti-inflammatory therapy at every step, minimizing reliance on short-acting β 2 \beta_2 β 2 ​ -agonist (SABA) monotherapy to reduce the risk of severe exacerbations and asthma-related mortality.

Maintenance and Reliever Therapy (MART) vs. Traditional Stepwise Regimens

MART Strategy: Utilizes a single inhaler containing an inhaled corticosteroid (ICS; budesonide or beclometasone) combined with the rapid-onset, long-acting β 2 \beta_2 β 2 ​ -agonist formoterol . Because formoterol has a rapid onset of action (1–3 minutes) identical to salbutamol, patients take regular daily maintenance doses and use the same inhaler for as-needed symptom relief, automatically titrating their anti-inflammatory ICS dose during early flare-ups.

Legacy stepwise ladder (pre-2024 BTS/SIGN, still quoted by older question banks - know it, but know it has been superseded for chronic management by the 2024 joint guideline):

Step 1: As-needed SABA alone for patients with very infrequent, short-lived symptoms and normal baseline lung function (or low-dose ICS taken concurrently whenever SABA is inhaled).

Step 2: Regular low-dose ICS (e.g., beclometasone dipropionate 200 – 400 μ g/day 200\text{–}400\ \mu\text{g/day} 200 – 400 μ g/day or budesonide 200 – 400 μ g/day 200\text{–}400\ \mu\text{g/day} 200 – 400 μ g/day ) plus SABA as needed.

Step 3 (Add-on Therapy): Add a Long-Acting β 2 \beta_2 β 2 ​ -Agonist (LABA; formoterol or salmeterol) in a fixed-dose combination with low-dose ICS, or initiate a low-dose ICS/formoterol MART regimen.

Step 4: Increase ICS to medium dose ( 400 – 800 μ g/day 400\text{–}800\ \mu\text{g/day} 400 – 800 μ g/day beclometasone equivalent), or add a Leukotriene Receptor Antagonist (LTRA) (montelukast 10 mg 10\text{ mg} 10 mg oral daily; particularly effective in aspirin-exacerbated respiratory disease [AERD / Samter's triad: asthma, nasal polyps, aspirin sensitivity] and exercise-induced bronchoconstriction) or a Long-Acting Muscarinic Antagonist (LAMA) (tiotropium Respimat soft mist 5 μ g 5\ \mu\text{g} 5 μ g daily).

Step 5 (Severe Refractory Asthma): High-dose ICS ( > 800 μ g/day > 800\ \mu\text{g/day} > 800 μ g/day ), trial of oral theophylline (phosphodiesterase inhibitor; narrow therapeutic window, target serum level 10 – 20 mg/L 10\text{–}20\text{ mg/L} 10 – 20 mg/L ), maintenance oral prednisolone (lowest effective dose), and formal referral to a dedicated severe asthma centre for biological phenotyping.

Targeted Biologic Therapies for Severe Refractory Asthma

Anti-IgE (Omalizumab): Subcutaneous humanized monoclonal antibody targeting free circulating IgE. Indicated in severe persistent allergic asthma with documented positive skin-prick test or specific IgE to perennial aeroallergens, total serum IgE 30 – 1500 IU/mL \text{IgE } 30\text{–}1500\text{ IU/mL} IgE 30 – 1500 IU/mL , and frequent exacerbations.

Anti-IL-5 Pathways: IL-5 is the cardinal cytokine governing eosinophil differentiation, activation, and survival. Indicated for severe refractory eosinophilic asthma (peripheral blood eosinophils ≥ 300 cells/ μ L \ge 300\text{ cells/}\mu\text{L} ≥ 300 cells/ μ L ):

Mepolizumab & Reslizumab: Neutralize circulating IL-5 ligand.

Benralizumab: Directed against the IL-5 receptor α \alpha α -subunit (IL-5R α \alpha α ), triggering antibody-dependent cell-mediated cytotoxicity (ADCC) by natural killer cells, producing near-complete eosinophil depletion.

Anti-IL-4R α \alpha α (Dupilumab): Monoclonal antibody targeting the α \alpha α -subunit of the IL-4 receptor, simultaneously blocking IL-4 and IL-13 signaling. Reduces exacerbations and improves FEV 1 \text{FEV}_1 FEV 1 ​ in severe eosinophilic or FeNO-driven asthma.

Anti-TSLP (Tezepelumab): Targets thymic stromal lymphopoietin (TSLP), an epithelial alarmin acting upstream of the inflammatory cascade; effective across both eosinophilic and non-eosinophilic severe asthma phenotypes.

3. Acute Severe vs. Life-Threatening Asthma: Recognition & Resuscitation

Correct clinical stratification dictates the urgency of intervention and immediate level of care.

Classification Clinical Criteria Arterial Blood Gas (ABG) & PEF Parameters

Moderate Exacerbation Increasing symptoms; PEF 50 – 75 % 50\text{–}75\% 50 – 75% best or predicted; can complete full sentences in one breath Normal respiratory rate; HR < 110 bpm \text{HR} < 110\text{ bpm} HR < 110 bpm ; SpO 2 ≥ 92 % \text{SpO}_2 \ge 92\% SpO 2 ​ ≥ 92% on ambient air

Acute Severe Asthma Any one of:; • PEF 33 – 50 % 33\text{–}50\% 33 – 50% best/predicted; • Respiratory rate ≥ 25 breaths/min \ge 25\text{ breaths/min} ≥ 25 breaths/min ; • Heart rate ≥ 110 beats/min \ge 110\text{ beats/min} ≥ 110 beats/min ; • Inability to complete sentences in one breath SpO 2 ≥ 92 % \text{SpO}_2 \ge 92\% SpO 2 ​ ≥ 92% ; low PaCO 2 \text{PaCO}_2 PaCO 2 ​ ( < 4.6 kPa < 4.6\text{ kPa} < 4.6 kPa / 35 mmHg 35\text{ mmHg} 35 mmHg ) secondary to tachypnoea-induced hyperventilation

Life-Threatening Asthma Any one of:; • PEF < 33 % < 33\% < 33% best/predicted; • SpO 2 < 92 % \text{SpO}_2 < 92\% SpO 2 ​ < 92% on air or PaO 2 < 8.0 kPa \text{PaO}_2 < 8.0\text{ kPa} PaO 2 ​ < 8.0 kPa ; • Normal or elevated PaCO 2 \text{PaCO}_2 PaCO 2 ​ ( > 4.6 kPa > 4.6\text{ kPa} > 4.6 kPa ) ; • Silent chest (loss of wheeze due to critically low airflow); • Cyanosis or feeble respiratory effort; • Bradycardia, hypotension, or cardiac dysrhythmia; • Diaphragmatic exhaustion, confusion, or coma Normal/high PaCO 2 \text{PaCO}_2 PaCO 2 ​ is a medical emergency indicating respiratory muscle fatigue and impending fatal arrest; severe lactic and respiratory acidosis

Near-Fatal Asthma Deteriorating respiratory mechanics with worsening acidosis Hypercapnia with profound acidaemia ( pH < 7.20 \text{pH} < 7.20 pH < 7.20 , PaCO 2 > 6.0 kPa \text{PaCO}_2 > 6.0\text{ kPa} PaCO 2 ​ > 6.0 kPa ) requiring mechanical ventilation

Emergency Management Protocol (BTS/SIGN acute asthma guidance, outside the scope of NG245)

Oxygen: High-flow oxygen via reservoir mask to achieve target SpO 2 94 – 98 % \text{SpO}_2\ 94\text{–}98\% SpO 2 ​ 94 – 98% . (Unlike COPD, hypoxic drive suppression is not a concern; severe hypoxaemia precipitates fatal ventricular arrhythmias).

Nebulised β 2 \beta_2 β 2 ​ -Agonists: Salbutamol 5 mg 5\text{ mg} 5 mg driven by oxygen ( 6 – 8 L/min 6\text{–}8\text{ L/min} 6 – 8 L/min ), repeated every 15–30 minutes or administered via continuous nebulisation ( 10 mg/hr 10\text{ mg/hr} 10 mg/hr ).

Nebulised Anticholinergic: Ipratropium bromide 500 μ g 500\ \mu\text{g} 500 μ g added to salbutamol nebulisers every 4–6 hours (or every 20 minutes in acute severe/life-threatening attacks).

Systemic Corticosteroids: Oral prednisolone 40 – 50 mg 40\text{–}50\text{ mg} 40 – 50 mg daily for at least 5 days (or IV hydrocortisone 100 mg 100\text{ mg} 100 mg 6-hourly if the patient is vomiting, exhausted, or unable to swallow).

Intravenous Magnesium Sulphate: 1.2 – 2.0 g 1.2\text{–}2.0\text{ g} 1.2 – 2.0 g IV infusion over 20 minutes for patients with acute severe asthma not responding to initial nebulisers or those presenting with life-threatening features. Acts by blocking smooth muscle calcium influx, promoting rapid bronchial relaxation.

Intravenous Aminophylline: Consider in ICU/HDU settings if unresponsive to inhaled bronchodilators and IV magnesium ( 5 mg/kg 5\text{ mg/kg} 5 mg/kg loading dose over 20 minutes if not on maintenance theophylline, followed by 0.5 – 0.7 mg/kg/hr 0.5\text{–}0.7\text{ mg/kg/hr} 0.5 – 0.7 mg/kg/hr infusion). Requires therapeutic drug monitoring.

Intubation & Invasive Mechanical Ventilation: Mandatory indications include respiratory arrest, profound hypercapnic coma, deteriorating exhaustion, or refractory severe hypoxia despite maximal medical therapy.